Hepion pharma has publshed a pres releaes regarding the CRV431 efficacy evaluation study for kidney fibrosis we have provied.

Hepion pharma, which is our client, has announced the results of pharmacology study using a UUO mouse model.


CRV431 is a cyclophillin inhibitor. In addition to the UUO mouse model, this compound exerts its anti-fibrosis effects in other fibrosis models such as the STAMTM mouse model, and is expected for future clinical development.


For detail information, see the Hepion pharma's press release.